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Acute myeloid leukemia (AML) is characterized by
recurrent mutations that affect the epigenetic re-
gulatory machinery and signaling molecules, leading
to a block in hematopoietic differentiation. Cons-
titutive signaling from mutated growth factor recep-
tors is a major driver of leukemic growth, but how
aberrant signaling affects the epigenome in AML
is less understood. Furthermore, AML cells undergo
extensive clonal evolution, and the mutations in sig-
naling genes are often secondary events. To eluci-
date how chronic growth factor signaling alters the
transcriptional network in AML, we performed a sys-
tem-wide multi-omics study of primary cells from
patients suffering from AML with internal tandem
duplications in the FLT3 transmembrane domain
(FLT3-ITD). This strategy revealed cooperation be-
tween the MAP kinase (MAPK) inducible transcrip-
tion factor AP-1 and RUNX1 as a major driver of a
common, FLT3-ITD-specific gene expression and
chromatin signature, demonstrating a major impact
of MAPK signaling pathways in shaping the epige-
nome of FLT3-ITD AML.
INTRODUCTION
In cancer, genes encoding signaling molecules and transcription
factors (TFs) can becomemutated, thereby leading to changes in
homeostatic gene regulatory networks, and a block in the normal
program of terminal differentiation. This is also true for acute
myeloid leukemia (AML). AML is a heterogeneous disease thatis caused by multiple mutations that affect normal blood cell
development from hematopoietic stem cells (HSCs) and prime
developing cells to becomemalignant. However, during the pro-
gression of the leukemic state, pre-leukemic and leukemic cells
undergo clonal evolution creating heterogeneous cell popula-
tions with different functional properties. In recent years it has
become clear that the majority of initial mutations occur in genes
encoding transcriptional and epigenetic regulators (Corces-Zim-
merman et al., 2014; Corces-Zimmerman and Majeti, 2014).
A few studies have examined in a system-wide fashion how
leukemic TFs reprogram chromatin and establish specific epige-
netic signatures and gene expression programs (Prange et al.,
2014). An example for this notion is the case of AML with
t(8;21) chromosomal translocation, which gives rise to the fusion
protein RUNX1/ETO. This aberrant TF competes with RUNX1 for
its binding motifs, leading to epigenetic reprogramming with a
block in myeloid differentiation and the concomitant activation
of a precursor-like AML-specific transcriptional network (Mar-
tens et al., 2012; Ptasinska et al., 2012, 2014). However, in the
case of karyotypically normal (KN) AML, it has proved to be
much harder to identify consistent patterns of deregulation asso-
ciated with specific mutations. This difficulty is due to (1) the het-
erogeneous nature of the combinations of underlying mutations
and (2) the fact that AML cells often span a range of differentia-
tion states. There is the added complexity that mutations in
genes encoding signaling molecules tend to appear late in the
process of leukemogenesis, making it harder to definitively link
them to consistent target gene alteration (Corces-Zimmerman
et al., 2014). Some of the most frequent secondary mutations
found in AML are in tyrosine kinase receptors such as FLT3
and KIT, which are rendered constitutively active (Masson and
Ro¨nnstrand, 2009). These receptors normally control the regu-
lated growth and survival of myeloid progenitor cells. Mutations
deregulate this process, thus effectively cutting off cancer cellsCell Reports 12, 821–836, August 4, 2015 ª2015 The Authors 821
AB C
D
E F
Figure 1. FLT3-ITD+ AML Displays a Characteristic mRNA Expression Profile
(A) PCR amplification of the transmembrane coding region of the FLT3 gene used to identify ITDmutations. On the left are the sizes of the DNAmarker bands (M).
Below are the estimated numbers of normal and mutated FLT3 alleles.
(B) Hierarchical clustering of Pearson correlation coefficients of mRNA values. For each sample the mutations present in the most commonly mutated genes are
indicated as M in the table underneath.
(C–F) Identification of genes that differ by at least 2-fold in a comparison of the average log2mRNAmicroarray values for a core group of three ITD+ AML samples
(ITD1, ITD2, and ITD3) to the equivalent values determined from either the average of two independent PBSC samples (C), the average of four WT FLT3 AML
samples (WT2, WT3, WT5, and WT7), for CD14+ bone marrow cells (E), or a second group of ITD+ AML samples (ITD4, ITD6, ITD7, and ITD8) used here for
(legend continued on next page)
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from normal growth regulating controls. However, we currently
know very little about howmutations in signalingmolecule genes
impact on gene expression and whether they also establish a
common epigenetic signature.
To address this question, we focused on the identification of
changes in the chromatin landscape and patterns of gene
expression that are driven by constitutive activation of intracel-
lular signaling pathways and concentrated on KN-AML with in-
ternal tandem duplications (ITDs) in the FLT3 transmembrane
domain as a paradigm. FLT3-ITD mutations are found in 25%
of KN-AML and lead to constitutive activation of the downstream
mitogen-activated protein kinase (MAPK), AKT, and signal trans-
ducer and activator of transcription (STAT) signaling pathways
linked to FLT3 (Stirewalt and Radich, 2003; Thiede et al.,
2002). FLT3-ITD frequently acts as a partner in AML with other
mutations such as those in transcription factors, epigenetic reg-
ulators, and Nucleophosmin (NPM1). Tyrosine kinase receptor
signaling has a direct influence on multiple signaling pathways
(Gu et al., 2011; Scholl et al., 2008) and the activities of many
TFs (Goyama et al., 2014; Yordy and Muise-Helmericks, 2000),
but could also signal to chromatin directly (Badeaux and Shi,
2013; Dawson et al., 2009; Ray et al., 2013). Our goal was there-
fore to examine whether the presence of the FLT3-ITD leads to
the establishment of a common epigenetic signature. To this
end we mapped open regions of chromatin that exist as DNase
I hypersensitive sites (DHSs) as this identifies active regulatory
elements (Cockerill, 2011). Using complementary genome-
wide analyses of gene expression and regulation in primary
AML cells, we show that the FLT3-ITD mutation is associated
with extensive changes in the epigenetic landscape and report
a FLT3-ITD-specific gene expression signature that is associ-
ated with FLT3-ITD-specific DHSs. The integration of these
global data reveals a cooperation between the MAPK inducible
transcription factor AP-1 and RUNX1 as two of the main drivers
of a FLT3-ITD-specific open chromatin signature.
RESULTS
System-wide Genomic and Epigenomic Analysis of
Karyotypically Normal AML
In order to define the specific genomic targets of aberrant
signaling in KN AML with the FLT3-ITD mutation, we purified un-
differentiated CD34 or CD117 positive cells, or obtained amono-
nuclear fraction comprising greater than 92% undifferentiated
blast cells, either from peripheral blood or from bone marrow
of AML patients. This protocol avoided confounding issues
associated with contamination by differentiated cells expressing
markers unrelated to leukemogenesis. Profiles from AML cells
were compared to those of the CD34+ progenitor population
of mobilized peripheral blood stem cells (PBSCs). To identify
specific genetic and epigenetic signatures, we performed a
comprehensive set of genome-wide analyses that included (1)validation of the ITD+ pattern (F). The 134 genes that are consistently expressed a
are shown in red, and the remaining genes that are upregulated in at least (C) are s
2-fold lower in ITD+ AML compared to each of PBSCs, WT FLT3 AML, and CD14+
(B) are shown in green. (D) Average log2mRNA values for the specific groups of 13
analysis, with the SD for mRNA expression shown as error bars.global mRNAmicroarray analysis to identify aberrantly regulated
genes, (2) a DNA sequence screen for exonicmutations within 55
candidate myeloid oncogenes and tumor suppressor genes to
uncover pathways responsible for aberrant gene expression pat-
terns (Table S1), (3) global DNase sequencing (DNase-seq) map-
ping of DHS patterns to identify aberrantly activated (and absent)
cis-regulatory elements, (4) identification of regions within DHSs
protected from DNase I digestion (digital footprints), and the un-
derlying specific motifs bound by TFs, (5) chromatin immunopre-
cipitation sequencing (ChIP-seq) assays to detect specific pro-
teins bound at DHSs, and (6) DNA methylation array analysis of
450,000 CG sites to detect epigenetically silenced loci. These
analyses included 19 KN AML samples, of which 9 were from
FLT3-ITD+ patients. Because the exon sequencing screen was
unable to detect all of the FLT3-ITDmutations, which vary greatly
in size and location, we confirmed the predicted FLT3-ITD status
by PCR analyses (Figure 1A), which indicated that the ITD had
occurred on both alleles in three of the samples (ITD3, ITD5,
and ITD7), while ITD4 had two different forms of the ITD muta-
tion. Data File S1 describes all of themutations in all our samples,
which were found in 21 different genes, plus their allele fre-
quencies. Most of these mutations and FLT3 PCR products
were detected at levels close to 50% or 100%, indicating that
these samples were clonal and that some mutations such as
those in JAK2were bi-allelic. Of the nine ITD+ patients, one sam-
ple had no other defined mutations (ITD1), and this became the
prototype ITD+ sample anchoring this study. Three of the pa-
tients with wild-type (WT) FLT3 hadmutations in genes encoding
other signaling molecules linked to FLT3 signaling pathways,
which included NRAS, PTN11, SOCS1, and JAK2, which might
therefore share some common features with FLT3-ITD+ AML.
SOCS1 mutations are also known to cooperate with FLT3-ITD
in AML (Reddy et al., 2012).
AMLwith FLT3-ITD Displays a Specific Gene Expression
Profile
We used microarray analysis to define mRNA levels for 22,000
genes for AML samples and in 2 independent samples of CD34+
PBSCs. Hierarchical clustering of the Pearson correlation coeffi-
cients was then used to identify similarities and differences
between these AMLs (Figure 1B). This analysis included seven
FLT3-ITD+ AMLs, five AMLs with wild-type (WT) FLT3 (and no
other known receptormutations), and oneAMLwith an activating
JAK2 mutation (and WT FLT3). The seven ITD+ AMLs formed a
discrete cluster with high correlation coefficients, while the five
WT FLT3 AMLs clustered more closely with the PBSCs, and the
JAK2 mutated AML had a pattern distinctly different to all the
other samples. The parallel mutation analysis revealed thatmuta-
tions in the epigenetic regulators DNMT3A and TET2 were
divided between the FLT3-ITD+ andWT FLT3 groups, andmuta-
tions in the genes encoding the TFsRUNX1,GATA2, andC/EBPa
occurred predominantly in theWT FLT3 AMLs. NPM1mutations,t 2-fold higher levels in ITD+ AML in each of the three comparisons in (C) and (E)
hown in blue. In (C) we also highlight 77 genes with values that are consistently
cells in black, and the remaining genes that are also downregulated at least in
4 upregulated and 77 downregulated genes in each of the 5 groups used in this
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which frequently partner FLT3-ITD, were restricted to the FLT3-
ITD+ AML cluster, but could not alone account for the observed
patterns as they did not independently cluster together.
To identify a set of genes specifically deregulated in FLT3-
ITD+ AML, we focused on the most related samples from each
group and independently analyzed expression data from three
core ITD+ AMLs (ITD1, ITD2, and ITD3) and four core WT FLT3
AMLs (WT2,WT3,WT5, andWT7), for whichwe also had accom-
panying DHS data. The three ITD+ AMLs included two with
mutated NPM1 (ITD2 and ITD3) plus ITD1 with no other defined
mutations (Data File S1). We compared the average log2 mRNA
microarray values with those for CD34+ PBSCs. As an additional
control and to assess the stage of the differentiation block, we
also compared these values with those from normal bone-
marrow derived CD14+ myeloid cells. We used this second cri-
terion to assist in the identification of artifacts arising from high
levels of gene expression within minor subsets of more differen-
tiated monocytic cells.
Within the core group of 3 ITD+ AMLs, we identified 730 upre-
gulated genes with average log2 values at least 1.0 above
PBSCs, (and absolute log2 values of at least 6.5 to select genes
at least 1 log above background), plus 1,021 downregulated
genes with values at least 1.0 below that of PBSCs (blue and
green dots, Figure 1C). However, only 134 of the upregulated
genes and 77 of the downregulated genes maintained the
same specific pattern of deregulation relative to both the WT
FLT3 AML subset and the CD14+ve cells (Figures 1C–1E, repre-
sented by red and black dots). Note that some of the 730 genes
upregulated in ITD+ cells were expressed at very high levels in
CD14+ cells, meaning that the elevated values may have arisen
from a minor contamination with more differentiated cells.
The 134 ITD-specific genes were on average expressed at levels
4-fold higher than in PBSCs, WT FLT3 AML, and CD14+ve cells
(Figure 1D). Conversely, the 77 downregulated genes were on
average expressed at levels 4-fold lower than the other three
cell types. We confirmed the generality of these observations
by demonstrating that the gene expression profile for the genes
upregulated in the core ITD+ group was essentially identical to
the average mRNA profile observed for an additional group of
four other ITD+ AMLs (ITD4, ITD6, ITD7, and ITD8) (Figure 1F).
These analyses highlighted the need formore than one reference
cell type when assessing expression patterns to identify true
FLT3-ITD responsive genes. Our data also suggest that the
block in differentiation in the FLT3-ITD+ AML occurs further
down the myeloid differentiation pathway as indicated by the
presence of the many genes expressed at levels similar to those
in more mature CD14+ve cells (and the WT FLT3 AML), but
higher than in PBSCs.
The average values for mRNA expression for the above two
groups of deregulated genes are listed in Data File S2. They
include upregulated genes that could influence the development
of AML cells such as genes encoding (1) the transcriptional re-
gulators FOXC1, PRDM16 (MEL1), and NFIX, (2) growth factor
receptor genes such as IL2RA, IL3RA, TNFSF9, TNFRSF4, and
TNFRSF18, (3) additional genes influencing growth and survival
such as CCNA1 (Cyclin A), PTP4A3 (PRL3), and IGFBP2, (4)
genes controlling differentiation such as the HOXB2 to HOXB6
cluster, and PBX3, (5) genes controlling homing such as the che-824 Cell Reports 12, 821–836, August 4, 2015 ª2015 The Authorsmokine genes CCL1 and CCL5, and (6) genes for proteases that
are known to remodel tissues and enhance migration such as
CTSG, ADAMTS14,MMP15, and (7) a gene cluster that includes
the protease genes ELANE,PRTN3, andAZU1 aswell as LPPR3.
The upregulated class of genes also contained other potentially
important genes regulating signaling and migration such as
AK2 (adenylate cyclase), DSC2 (a protein involved in cell adhe-
sion), and the gene encoding the macrophage scavenger recep-
tor SCARA3, whichmay be related to the fact that FLT3-ITD cells
increase ROS production (Sallmyr et al., 2008). FOXC1 encodes
a pioneer-type transcription factor (Zaret and Carroll, 2011).
PRDM16 is related to the cancer-promoting histonemethyl trans-
ferase gene EVI1, and both EVI1 and PRDM16 are activated via
RAS mutations in models of myeloid leukemia (Wolf et al., 2013).
The expression patterns of seven of these upregulated genes,
plus TBP as a control, are shown in Figure S1A for all of the sam-
ples analyzed. Within the core cluster of three ITD+ AMLs,
FOXC1 was the only FOX gene significantly upregulated in
ITD+ AML compared to the cluster of four WT FLT3 AMLs,
while FOXO1 expression was downregulated (Figure S1B).
Most notable of the 77 downregulated genes was a group of
10 HLA class II genes that were consistently downregulated in
ITD+ AML and not in WT FLT3 AML (Figure S1C).
To validate the conclusions of our mRNA expression analysis,
we analyzed data from two published studies of much larger co-
horts of AML samples (Figure 2). For the ITD target genes iden-
tified above, we calculated the average mRNA levels for data
from (1) a study of 461 AML patients comparing FLT3 ITD+AML
samples with WT FLT3 AML samples (Verhaak et al., 2009) and
(2) a study of 200 patients from The Cancer Genome Atlas
(TCGA) Research Network comparing all samples with any
FLT3 mutations with WT FLT3 AML samples (Cancer Genome
Atlas Research Network, 2013). This confirmed that on average
the above 134 upregulated genes and 77 downregulated genes
displayed the same behavior in these much larger studies (Fig-
ures 2A and 2B). Several genes controlling gene expression or
cell growthwere confirmed as upregulated ITD target genes (Fig-
ure 2A), including RUNX1, IGFBP2, PRDM16, PTP4A3, and
CCNA1 (Figure 2C).
AML with FLT3-ITD Displays a Distinct Chromatin
Signature
Tumor-specific DHSs patterns provide vital clues regarding the
nature of TFs involved in tumorigenesis (Kreher et al., 2014). To
identify DHSs specifically enriched in the ITD+ AMLs, we per-
formed DNase-seq on a matched set of five ITD+ AMLs, five
AMLs with WT FLT3, and two independent samples of CD34+
PBSCs. In a global evaluation of all the DHSs detected, we
first identified all peaks for each dataset and determined the
sequence tag counts for 400-bp regions centered on each
peak. We then divided the peaks into the two separate groups
of distal DHSs and promoter associated DHSs. Because we
found that the greatest differences between the ITD+ and WT
FLT3 AMLs were seen for the distal DHSs, we focused most of
our subsequent more detailed analyses on this group. Previous
global studies of transcriptional networks have similarly found
that tissue-specific patterns are more associated with distal
rather than proximal cis-elements (Heinz et al., 2010). For the
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Figure 2. FLT3-ITD Consistently Deregu-
lates the Same Genes in AML
(A–C) Average mRNA microarray values for FLT3-
ITD target genes in 2 datasets obtained from 461
(Verhaak et al., 2009) or 200 (Cancer Genome Atlas
Research Network, 2013) AML samples.
(A) Average profiles for 134 upregulated genes,
with a subset of validated genes listed on the right.
(B) Average profiles for 77 downregulated genes.
(C) Profiles for individual upregulated genes.initial comparisons, we performed hierarchical correlation clus-
tering of the DNase-seq peak data (Figure 3A). As seen for the
mRNA microarray values, the ITD+ samples clustered together
as a discrete group distinct from both the WT FLT AMLs and
the PBSCs. Parallel analysis of mutations in these samples again
suggested that the ITD mutation had the greatest influence in
defining the overall patterns of distal DHSs (Figure 3A, bottom).
Interestingly, within the WT FLT3 group the two AMLs with
mutated RUNX1 genes clustered together, as did the two sam-
ples with both GATA2 and CEBPA mutations.
Figure 3B depicts the genome browser view of a gene cluster
that includes the myeloid genes LPPR3, AZU1, PRTN3, ELANE,
andCFD. Four of these closely linked genes were included in the
group of 134 highly ITD-specific mRNAs listed in Data File S2.
This region includes an ITD-specific DHS within an intron of
MED16, which was essentially absent in both CD34+ PBSCs
and in AMLs with WT FLT3. Figure 3C reveals a strong trend
for specific upregulation of expression of the whole cluster ofCell Reports 12, 821–8five genes in the ITD+ samples (shown
in red), with a modest upregulation of
MED16, which harbors the specific DHS,
and no upregulation of the flanking genes.
With the exception of AML sample WT1,
which carries a NRAS mutation, these up-
regulated genes were actually downregu-
lated in AML with WT FLT3 (shown in
green).
To visualize the overall specific DHS
pattern in FLT3-ITD AML, we calculated
the ratios for all of the distal DNase-seq
peaks for each of the AML samples de-
picted in Figure 3A relative to the same re-
gions, using a PBSC DNase-seq dataset
that was sequenced at high read depth.
These ratios were then used for hierarchi-
cal clustering of the values, which are rep-
resented as a heatmap in Figure 3D. This
analysis identified a cluster of 2,000
DHSs that were consistently enriched in
the ITD+ samples and under-enriched in
the WT FLT3 samples. Conversely, a
separate cluster of DHSswas consistently
downregulated in ITD+ AML and upregu-
lated in the WT FLT3 samples, indicating
that FLT3-ITD has both positive and nega-
tive effects on DHSs.We next identified the full complement of FLT3-ITD-specific
DHS peaks by calculating ratios of DNase-seq tag counts for
all distal peaks detected in each AML sample and/or the PBSCs.
Peaks were ranked in order of increasing DNase-seq tag count
ratios for the AML sample relative to CD34+ PBSCs, and the
DNase-seq data were plotted in order of increasing ratio as den-
sity maps spanning each 400-bp window. In the case of the
prototype ITD+ AML sample ITD1 (which had no other defined
mutations), we identified a total of 19,551 distal peaks present
either in the ITD1 or PBSC dataset. The DNase-seq density
maps are shown side-by-side in Figure 3E for both PBSCs and
ITD1, revealing that most DHSs spanned200–250 bp and iden-
tifying a group of 3,728 distal DHSs that were at least 2-fold more
intense in ITD1 (boxed region in Figure 3E). Parallel pair-wise an-
alyses were also performed comparing the distal peaks in ITD2
and in ITD3, and the promoter-associated DHSs in ITD1, ITD2,
and ITD3, with the equivalent regions in PBSCs (Figures S2A–
S2C). In each case we identified the subsets of DHSs that36, August 4, 2015 ª2015 The Authors 825
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Figure 3. FLT3-ITD+ AML Has a Characteristic Chromatin Signature
(A) Hierarchical clustering of Pearson correlation coefficients of DHS peaks. For each sample the mutations present in the most commonly mutated genes are
indicated as M in the table underneath.
(B and C) UCSC Genome Browser views of the DNase-seq patterns (B), and relative mRNA values (C) of genes surrounding an ITD+ AML-specific DHS inMED16
marked by a red oval, and a cluster of adjacent genes upregulated in ITD+ AML. mRNA values are shown as a ratio of the values detected in the AML samples
compared to PBSCs (red: up, green: down).
(D) Heatmap depicting hierarchical clustering of the relative DNase-seq signals seen in each distal DHS peak in each AML sample relative to PBSCs.
(E) Profiles of the DNase-seq signals within each 400-bp window centered on each peak for PBSC and ITD1, with peaks shown in the order of increasing DNase-
seq tag count signal for ITD1 relative to PBSC. This analysis includes the union of all peaks present in either ITD1 or in PBSC. Shown to the right of the DNase-seq
profiles are the relative mRNA expression values for genes with the nearest transcription start sites (TSS) in ITD1 relative to PBSC, and the DNA methylation
signals for the nearest TSS and for the DHS in ITD1 relative to PBSCs.
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were at least 2-fold more intense in the AML sample than in
PBSCs. The profiles of the average tag counts for the distal
DHSs are plotted in Figure S2D and reveal similar patterns of
deregulation in each of ITD1, ITD2, and ITD3. The parallel ana-
lyses of the promoter regions showed a less pronounced upre-
gulation of a small subset proximal DHSs in each of the ITD+
AML samples (Figure S2C).
To examine how the presence of DHSs impacted on the
expression of nearby genes, we plotted the relative AML/
PBSC mRNA expression levels for the genes nearest to each
DHS in the three core FLT3-ITD AML samples relative to PBSCs
(Figures 3E, S2A, and S2B). These heatmaps revealed a trend
for upregulation of the genes nearest to ITD-specific DHSs. In
parallel, we determined ratios for the level of DNA methylation
for CG elements covered by the Illumina 450K platform, and
we plotted heatmaps of this data for regions spanning both
the DHS site itself and the transcription start site of the nearest
gene for ITD1 and ITD2. This revealed a trend for DNA demethy-
lation of both the ITD-specific DHSs and the adjacent transcrip-
tion start sites (TSSs) and for increased DNA methylation in the
DHSs that were absent (Figures 2E and S2A). However, the
overall changes in DNA methylation were less pronounced
than the chromatin changes, suggesting that these may be sec-
ondary events.
Using the ranking defined in Figure 3E, we also carried out
direct side-by-side comparisons of the complete set of 19,551
distal ITD1/PBSC DHSs with each of the above datasets, plus
the data for CD14+ BM cells, and for 3 previously published
DHS datasets derived from normal CD34+ and CD14+ cells
from the NIH Epigenome Roadmap consortium (Bernstein
et al., 2010) plotted in the same order (Figure S2E). This
confirmed that (1) the DHS pattern for PBSCs resembled inde-
pendently derived equivalent CD34+ cell datasets, and (2) a
common subset of DHSs was upregulated in each of the ITD+
samples, and (3) the DHS patterns present in the two more
mature CD14+ cell datasets and the WT FLT3 AML samples
more closely resembled PBSCs than ITD+ AML (Figure S2E).
To better define these profiles, we used the relative DNase I sig-
nals to divide the DHSs into the three groups of (1) 2-fold down-
regulated, (2) less than 2-fold change, and (3) 2-fold upregulated
(as depicted to the left of Figures 3E and S2E). The average
DNase I profiles for each group are shown in Figure S2F. This
clearly demonstrates that other ITD+ AMLs shared the same
core of upregulated DHSs (group 3), whereas the patterns for
the WT FLT AMLs more closely resembled the patterns for
CD34+ and CD14+ cells. Last, but not least, we defined a
discrete subset of reproducibly upregulated ITD-specific DHSs
by determining the overlap between the FLT3-ITD-specific
DHSs of each of ITD1, ITD2, and ITD3, and we found that
1,216 of these DHSs were shared between each group with
high significance (Figure 4A). The locations of these DHSs are
defined in Data File S3. ITD2 and ITD3, which both have NPM1
mutations, were the most similar with 83% of the top ITD2 group
being part of the top ITD3 group. However, the NPM1mutation is
unlikely to be a major driver of this pattern because the upregu-
latedDHSs fromAML sampleWT1 (Figure 4B) andWT8 (data not
shown), which each carry an NPM1 mutation but WT FLT3,
showed non-significant overlap with the ITD+ group. An equiva-lent analysis of the DHSs that are 2-fold upregulated in 3 AML
samples with WT FLT3 (WT2, WT3, and WT5) also showed
non-significant overlap with each other and with just 29 of
the164 overlapping DHSs shared with the 1,216 ITD-specific
DHSs (Figure 4C).
ITD-Specific DHSs Are Associated with ITD-Specific
Genes and an Activation Signature
Gene ontology analysis of the genes located closest to the 1,216
distal ITD-specific DHSs identified a strong correlation with
genes linked to cell signaling and activation (Figure 4D). To
directly link the ITD-specific epigenetic signature with the gene
expression profile, we calculated the distance of each ITD-spe-
cific gene promoter region from the nearest upregulated DHS
for both the highly ITD-specific 134 genes (shown in red) and
for the additional genes included in the 730 upregulated genes
(shown in blue), and we depicted this relationship graphically in
Figure 4E. Interestingly, this revealed an increasing degree of
upregulation at the mRNA level for the genes closest to an
ITD-specific DHS. Examples of individual ITD-specific genes
close to ITD-specific DHSs are shown for SCARA3, WDR86,
and CTSG/GZMB in Figures 4F and 4G and for FOXC1, DSC2,
and AK2 in Figures S1, S3A, and S3B. More complex patterns
were seen for the HOXB cluster, where many DHSs were upre-
gulated in ITD+ AML (Figure S3A), in parallel with the cluster of
HOXB2 to HOXB6, and for a DHS in the C10orf128 locus, where
both C10orf128 locus and VSTM4 were included in the group of
134 ITD-specific mRNAs (Figure S3B). A different pattern was
seen for ID1, a previously defined ITD target gene (Tam et al.,
2008), which contains an ITD-specific DHS at –2 kb and was up-
regulated in ITD+ AML compared to most WT FLT3 AMLs, but
not compared to PBSC or normal CD14+ cells (Figure S3B).
Interestingly, ID1 is also regulated by a downstream STAT5-
dependent enhancer at +5 kb (Tam et al., 2008; Wood et al.,
2009). STAT5 is FLT3-ITD inducible (Mizuki et al., 2000). To
examine the role of STAT5 in the regulation of this and other
genes, we therefore measured genome-wide binding sites for
this factor by ChIP-seq. This experiment demonstrates that
the +5 kb element indeed binds STAT5 in the MV4-11 FLT3-
ITD cell line (Figure S3B). However, this DHS was not FLT3-
ITD-specific.
Overall, the ITD-specific genes were upregulated in either all
or most ITD+ samples (Figures 4F and S1A). However, ITD9 rep-
resented a notable exception to this pattern. Interestingly, this
patient carried a RUNX1 frameshift mutation, suggesting an
important role of RUNX1 in activating FLT3-ITD-specific genes.
Furthermore, the three samples carrying RUNX1 mutations
(labeled R) tended to have similar expression profiles (WT2,
ITD9, and WT3 in Figures 4, S1, and S3). Conversely, we also
noted that among these loci there were also numerous examples
of DHSs that were preferentially enhanced in both the ITD+AMLs
and in AML samples WT1 and/or WT6, which carry mutations in
signaling molecules (labeled with asterisks). AML sample WT1
carries an activating NRAS G12S mutation, which is a powerful
activator of the MAPK pathway. Hence, activating RAS muta-
tions with a concomitant upregulation of MAPK signaling may
activate a subset of genes and DHSs that we defined here as
FLT3-ITD targets.Cell Reports 12, 821–836, August 4, 2015 ª2015 The Authors 827
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Taken together, our analysis demonstrates that in spite of the
presence of a wide variety of mutations, the presence of a chron-
ically active FLT3-ITD correlates with a common core epigenetic
signature that is associated with a distinct gene expression
pattern. In addition, our mutation data suggested a role for
both RUNX1 andMAPK signaling in activating FLT3-ITD-specific
DHSs.
FLT3-ITD-Specific DHSs Are Associated with Specific
DNA Binding Motifs for RUNX1 and AP-1, but Not STAT5
Having identified a FLT3-ITD+ AML-specific epigenetic signa-
ture, we investigated its underlying molecular basis by perform-
ing an unbiased search for enriched sequence motifs within
active chromatin regions using HOMER (Heinz et al., 2010) (Fig-
ure 5A). This analysis revealed that RUNX, AP-1, ETS, E-box, and
C/EBP motifs were the most common binding motifs present in
the top 1,216 ITD-specific DHSs, each being found in 18%–55%
of all sites. Interestingly, we also identified a motif for Forkhead
(FOX) family proteins, which was part of a composite FOX/E-
box motif that might recruit complexes containing both FOX
and HLH family TFs such as TAL1/SCL and LYL1, which function
together with RUNX, ETS, and GATA family TFs in the combina-
torial regulation blood stem cell development (Wilson et al.,
2010). We also saw an enrichment of motifs for the inducible
TFs NF-kB and ATF, but with less statistical significance. In order
to validate the above results, we plotted the coordinates of each
motif found back on to the coordinates of the DHSs, plotted in
the same order of increasing DHS ratio as above (Figure 5B).
We also plotted the rolling average of the numbers of each motif
found per DHS across the same series of DHSs (Figure 5C), plus
the average distributions of themotifs with each of the previously
defined three groups of distal ITD1/PBSC DHSs (Figure S4A). All
five motifs were present in the ITD-specific DHSs at levels sub-
stantially higher than the predicted random level (indicated by
the dashed lines in Figure 5C). Most of these motifs aligned
with the midpoints of the DHSs, suggesting that the two features
are functionally related. Both the FOX/E-box and the C/EBP mo-
tifs were preferentially enriched in the ITD-specific DHSs, repre-
sented as group 3 in Figure S4A. ITD-specific DHSs were also
highly enriched in motifs widely used in normal myeloid cells
(Heinz et al., 2013). RUNX, ETS, and AP-1 motifs were highly
abundant in both the ITD-specific DHSs and the DHSs that
were shared between the AML and the PBSCs. This suggests
that the FLT3-ITD signature involves a substantial degree of
redeployment of TFs driving the normal myeloid program.
We also looked directly for the presence of binding motifs of
other TFs linked to common signaling pathways that were notFigure 4. FLT3-ITD Mutations Are Associated with a Specific Subset o
(A–C) Venn diagrams depicting the overlaps between populations of DHSs that a
(A) Intersections between ITD1, ITD2, and ITD3.
(B) Intersections between ITD1, ITD2, and WT1, which has a NPM1 mutation.
(C) Intersections between WT2, WT3, and WT5.
(D) Gene ontology analysis of the genes closest to the 1,216 ITD-specific DHSs
(E) Plot of the relationship between the log2 mRNA fold change for genes upregul
the 134 ITD-specific genes (red), and the remainder of the 703 upregulated gene
(F and G) Log2mRNAmicroarray values (as in Figure S1) (F) and UCSCGenome B
genes SCARA3, WDR86, and CTSG/GZMB. ITD-specific DHSs are enclosed byamong the motifs found by HOMER, such as the FLT3-ITD
inducible TF STAT5 (Mizuki et al., 2000). However, we did not
see any significant enrichment for STAT motifs in ITD-specific
DHSs or for motifs linked to other signaling pathways, such as
interferon response factors (IRFs), which are commonmediators
of receptor signaling, or NFAT, which is a mediator of Ca2+
signaling (Figures S4A and S4B). These three classes of motifs
were present at low abundance and mostly showed an anti-cor-
relation with the ITD-specific DHSs. The average densities of
each motif across each the three groups of DHS are depicted
in Figure S4A. Because the TF GATA2 is important for blood
stem cell development (de Pater et al., 2013; Wilson et al.,
2010), we also analyzed the distribution of GATA motifs. These
motifs were most enriched in the PBSC-specific group 1 but
were depleted in the ITD-specific group 3 DHSs, providing
another indication that ITD1 represents a more mature myeloid
cell.
To evaluate the role of STAT5 in shaping the FLT3-ITD-specific
epigenetic signature, we integrated theDHS datawith the STAT5
ChIP-data from FLT3-ITD+ MV4-11 cells. This analysis revealed
STAT5 peaks in the HOXB,AK2, VSTM4/c10orf128, and ID1 loci,
but not at the above-defined ITD-specific DHSs (Figure S3).
Moreover, when STAT5 peaks were plotted alongside the
ITD1/PBSC DHS comparison, they were found to be broadly
distributed throughout the genome and predominantly in the
shared DHS group (Figure S4B). Furthermore, just 249 of the
9,572 STAT5 peaks detected were present within the group of
1,216 ITD-specific DHSs (Figure S4C). These data suggest that
STAT5 is binding predominantly at pre-existing DHSs and only
plays a minor role in maintaining the FLT3-ITD-specific DHSs.
A de novo motif analysis of the STAT5 ChIP peaks identified
a STAT consensus motif in 16% of these peaks and further
suggested that much of the STAT binding is in association
with DHSs containing ETS, RUNX, C/EBP, and AP-1 motifs
(Figure S4D).
A parallel analysis of DHSs and motifs associated with 380
ITD-specific promoter-associated DHSs revealed a similar ITD-
specific epigenetic and binding motif signature (Figures S4E
and S4F). Gene ontology analysis of the genes associated with
this group of DHSs also revealed a cell activation signature
similar to that seen for genes associated with the distal ITD-spe-
cific DHSs (Figure S4G).
RUNX1, AP-1, FOX/E-box, and C/EBP Motifs Are
Occupied in ITD-Specific DHSs
Our motif analysis pointed to a major role for RUNX and AP-1 in
activating FLT3-ITD-specific DHSs. However, the presence off DHSs
re 2-fold upregulated in AML samples compared to PBSCs (FC > 2).
defined in (A).
ated in ITD+ AML versus the distance to the nearest ITD-specific DHS for all of
s (blue) for genes located within 800 kb of an ITD-specific DHS.
rowser views for DNase-seq and RUNX1 ChIP-seq data (G) for the ITD-specific
red ovals.
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Figure 5. ITD-Specific DHSs Have a Specific Motif Signature and Bind RUNX1
(A) Result of de novo motif search of 1,216 ITD-specific DHSs using HOMER.
(B and C) Alignment of ITD-specific DHS motifs with distal DHSs present in either ITD1 or PBSCs (B) with the rolling averages of motif densities plotted
underneath (C).
(D–F) Analysis of RUNX1 ChIP-seq data comparing ITD1 (D), ITD4 (E), and PBSCs (F) plotted alongside the ITD1 and ITD4 DHS data. (F) Depiction of the rolling
averages of the ChIP signals.enriched motifs within specific DHSs does not necessarily mean
that they are occupied. To verify occupancy by RUNX1, we per-
formed ChIP-seq assays on ITD1, ITD4, and PBSCs (Figures 5D
and 5E). The average profiles of RUNX1 binding (Figure 5F)
closely mirrored the distribution of ITD-specific DHSs (Fig-
ure S2D) and RUNX motifs (Figure 5C). To account for the in-
crease in RUNX1-bound sites in the ITD+ cells, we examined830 Cell Reports 12, 821–836, August 4, 2015 ª2015 The AuthorsRUNX1 expression levels. RUNX1 expression was elevated in
most of the ITD+ AMLs and in the AML with JAK2 mutations
compared to normal CD34+ and CD14+ cells, but only in some
of the WT FLT3 AMLs (Figure 6A; manual PCR validation shown
in Figure S5A). A parallel PCR analysis confirmed that FOXC1
mRNA was also often upregulated in ITD+ AML (Figure S5B),
with both RUNX1 and FOXC1 being significantly increased in
each of the core ITD+ group of ITD1, ITD2, and ITD3. The upre-
gulation of RUNX1 expression may be in part due to the pres-
ence of an ITD-specific DHS within the RUNX1 gene 43 kb
downstream of the downstream promoter P2 (Figure 6B), which
contains seven motifs linked to ITD-specific DHSs (RUNX, ETS,
FOX, AP-1, and E-box) (Figure 6C). These motifs were also seen
in the ITD-specific DHSs associated with FOXC1, DSC2, AK2,
and ID1 (Figure S3) and in the SCARA3, CTSG, MDGA1,
MED16, GZMB, VSTM4/c10orf128, and CCNA1 ITD-specific
DHSs (Figure S5C). Notable among the 1,216 ITD+ DHSs was
a DHS near C8orf87 containing 5 FOX motifs, one of which
was the exact composite FOX/E-box motif defined in Figure 5A.
This DHS was 221 kb away from the highly ITD-specific gene
FAM92A1 (Figure S5D). In this case, the gene was again not ex-
pressed in AML samples with WT FLT3 unless they carried other
mutations in the signaling molecules NRAS or SOCS1 (ITD1 and
ITD6, marked by asterisks), or JAK2, and was also not upregu-
lated in samples carrying RUNX1 mutations.
AP-1 is highly relevant to this study because it normally func-
tions as a tightly regulated MAPK-inducible factor known to play
major roles in the control of cell growth, survival, and cancer
(Shaulian, 2010; Shaulian and Karin, 2002). To test for enhanced
AP-1 activity, we used electrophoretic mobility shift assays (EM-
SAs) to examine the levels of nuclear AP-1 DNA-binding activ-
ities in both FLT-ITD+ andWT FLT3myeloid cell lines (Figure 6D).
Both of the ITD+ cell lines MV4-11 and MOLM14 had high levels
of constitutive AP-1 activity, equivalent to the induced levels of
AP-1 seen in the WT FLT3 cell lines U937 and THP1. Because
AP-1 is a MAPK-inducible factor, we also used western blots
of MV4-11 cell proteins to look for evidence of FLT3-dependent
activation of MAPK signaling pathways (Figure 6E). This analysis
revealed FLT3-dependent phosphorylation of both ERK1/2 and
RSK2 (which are downstream of RAS signaling), which was sup-
pressed by small interfering RNA (siRNA) directed against FLT3.
This confirmed the FLT3-dependent activation not only of MAPK
and the STAT pathways but also of STAT5. Furthermore, quan-
titative RT-PCR analyses revealed suppression of expression
of several previously defined ITD-specific genes in MV4-11 cells
after treatment with either FLT3 siRNA or a combination of inhib-
itors directed against the MEK, JNK, and p38 MAPK pathways
(Figure 6F). We used ChIP to confirm that one partner of the
AP-1 complex, FOS, was bound to four ITD-specific DHSs in
MV4-11 cells (Figure 6G) that each contain AP-1 motifs (Fig-
ure S5C) and that RUNX1 was also bound to three of these
DHSs and to the CSF1R FIRE element (Ptasinska et al., 2014)
used here as a control for RUNX1 binding. In parallel we demon-
strated that either FLT3 siRNA or MAPK inhibitors were sufficient
to substantially diminish binding of FOS and RUNX1 to these
ITD-specific DHSs, to a greater extent than seen at the FIRE
RUNX site (Figure 6G). Last, but not least, we performed a
ChIP-seq analysis for FOS in MV4-11 cells treated with FLT3
siRNA, which demonstrated a global decrease in the binding of
FOS (Figure 6H). In summary, our data demonstrate that consti-
tutive FLT3-ITD signaling leads to chronic activation of AP-1 via
the MAPK pathway, which together with RUNX1 leads to chro-
matin remodeling and the activation of specific genes.
We next wanted to understand the role of other TFs in shaping
ITD-specific DHS and how they would work together. To findadditional evidence for the binding of these factors, we em-
ployed our recently developed Wellington algorithm that uses
DNase-seq data to perform genome-wide in silico DNase I foot-
printing of regulatory motifs (Piper et al., 2013). This methodol-
ogy determines statistically whether a given DNA sequence is
protected from DNase I digestion, thereby indicating that it is
occupied by a TF, as modeled in Figure 7A. Figure 7B depicts
the density of upper (red) and lower (green) strand DNase I cleav-
age sites detected in ITD1 and PBSCs at all 5,142 FLT3-ITD-spe-
cific predicted footprints and at the specific subset carrying AP-1
motifs. The black gap between the red and the green signal indi-
cates that the AP-1 motifs were occupied at a high frequency in
ITD+ cells, but not in PBSCs. This analysis provided convincing
evidence that AP-1 motifs are preferentially occupied in the
FLT3-ITD AML sample, even though ITD1 and PBSCs share
many DHSs that contain AP-1 motifs. These ITD-specific foot-
prints also included 63 STAT5 motifs and 226 STAT4 motifs
(some of which will be the same motif), but none of these were
associated with any of the 134 or 77 FLT3-ITD-specific upregu-
lated or downregulated genes.
A de novo search for motifs within the 5,142 footprints
revealed essentially the same signature as that of the 1,216
ITD-specific DHSs (Figure 7C), but with an additional motif for
Nuclear Factor 1 (NF1) that may be linked to the ITD-specific
upregulation ofNF1X, which contains an ITD-specific DHS occu-
pied by RUNX1 (data not shown). Figure 7D depicts the locations
of the footprinted ITD-specificmotifs on the ITD1/PBSCDHS co-
ordinates displayed above in Figures 3E and 5B, demonstrating
a close alignment with the DHS peak summits and with the
FOX/E-box, C/EBP, and NF-kB motifs each being preferentially
occupied in the ITD-specific DHSs. Occupied AP-1 motifs
were equally distributed between ITD1-specific DHSs and
DHSs shared with PBSCs, indicating constitutive binding of
AP-1 to the shared sites in FLT3-ITD AML. We confirmed the ex-
istence of footprints at many of the predicted protected motifs
by plotting the frequency of DNase I cleavage on the upper
and lower strand in ITD1, alongside the footprint probability pro-
files and the motifs in Figure S6A. The parallel analysis of foot-
prints in ITD2 showed similar results (not shown). To confirm
the ability of our algorithm to detect STAT footprints, we show
a footprint spanning the STAT motif, plus a second footprint
spanning ETS and AP-1 motifs within the ID1 +5 kb DHS in
ITD1 (Figure S6B). Overall, these results highlight (1) that gene
activation in ITD+ AML involves FLT3-ITD-driven constitutive
binding of normally inducible factors to pre-existing DHSs and
(2) that RUNX1 and AP-1 are associated with both pre-existing
and ITD-specific DHSs.
To examine, whether TFs binding to ITD-specific DHSs func-
tion in cooperation, we performed a bootstrapping analysis to
identify which specific footprinted motifs were co-localized
with 50 bp of each other (Figure 7E). This revealed a strong co-
association of the occupied FOX, E-box, C/EBP, RUNX1, and
AP-1 motifs within the same DHSs. Curiously, the ETS motifs
were not preferentially footprinted in the ITD-specific DHSs,
and they did not co-localize with the other ITD-specific motifs,
which may tie in with the finding that PU.1 activity is downregu-
lated in FLT3-ITD (Gerloff et al., 2015). In summary, these ana-
lyses demonstrate that the establishment of FLT3-ITD-specificCell Reports 12, 821–836, August 4, 2015 ª2015 The Authors 831
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Figure 6. AP-1 and RUNX Pathways Are Activated in ITD+ AML
(A) Log2 RUNX1 mRNA microarray values.
(B) UCSC Genome Browser view for RUNX1 DNase-seq.
(legend continued on next page)
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DHSs is mediated by the interaction of a limited set of constitu-
tive and inducible transcription factors.
DISCUSSION
A two-hit model of leukemogenesis is commonly accepted
whereby a mutation in a transcriptional or epigenetic regulator
gene impacting on gene expression and differentiation (class II
mutation) cooperates with a mutation in a gene such as a
signaling molecule regulating growth (class I mutation) (Renne-
ville et al., 2008). Here we show at the systems level, in primary
cells from patients, that this distinction is becoming blurred,
with signaling having wide-ranging impacts on gene expression.
Our study uncovers a significant role for chronic signaling by a
mutated FLT3 growth factor receptor to the nucleus and demon-
strates a profound impact of aberrant signaling on transcription
factor binding and FLT3-ITD-specific gene expression. Our
findings are consistent with the model depicted in Figure 7F in
which aberrant FLT3-signaling activates both STAT and MAPK
signaling. The latter, via the activation of inducible transcription
factors such as AP-1/ATF family members and NF-kB, upregu-
lates genes such as RUNX1 and FOXC1, which in cooperation
with other factors, including C/EBP, ETS, and E-box family
members, activate specific cis-regulatory elements driving the
expression of many target genes. A similar cooperation between
RUNX1 and AP-1 in response to MAPK signaling has been seen
during megakaryocyte differentiation (Pencovich et al., 2011).
Moreover, our mutation data indicate that alternate mutation of
another member of the MAPK pathway (NRAS) may upregulate
related sets of cis-regulatory elements. Furthermore, the muta-
tion of RUNX1 disturbs the FLT3-ITD-specific expression pattern
andmay also influence the expression of the FOXC1 gene, which
is not highly expressed in the patient containing mutant RUNX1
(ITD9) (Figure S1A). FOXC1 is itself linked to an ITD-specific DHS
that contains three RUNX consensus motifs and that binds
RUNX1 in ITD1 (Figure S3A).
A surprise finding from our study was the absence of enriched
STAT motifs in our global analysis of ITD-specific DHSs in spite
of overwhelming evidence (also from this study) that FLT3-ITD
feeds into the STAT pathway and is required for enhanced trans-
location of STAT5 into the nucleus and leukemic survival (Chat-
terjee et al., 2014; Gu et al., 2011; Masson and Ro¨nnstrand,
2009; Mizuki et al., 2000; Zhang et al., 2000). Furthermore, the
data fromMV4-11 cells suggested that STAT5 is bound predom-
inantly at pre-existing DHSs that are shared with CD34+ cells,
not STAT5-dependent DHSs, and thus is not involved in opening
up additional FLT3-ITD-dependent DHSs. It is also possible that(C) Sequence of the ITD-specific RUNX1 +43-kb DHS with the indicated sequen
(D) EMSA using nuclear extracts from the indicated cell lines grown in the presenc
calcium ionophore A23187 (PMA/I) to induce AP-1 activity. Some assays include
(E) Western blot analyses extracts from ITD+ MV4-11 cells treated with FLT3 or
(F) RT-QPCR analysis of ITD target gene mRNA expression after treatment of M
inhibitors PD98059, SP600125, and SB202190 directed against MEK1/2, JNK, an
Values were calculated relative to GAPDH.
(G) ChIP analyses of FOS and RUNX1 binding to ITD-specific DHSs, with normal Ig
region in the inactive IVL locus.
(H) Average FOS ChIP peak profiles obtained from MV4-11 cells treated with eitSTAT5 binding to its targets may be only be required for the up-
regulation of a limited set of survival genes (such as MYC or
BCLXL) (Chatterjee et al., 2014) and so is simply not present at
most ITD-specific DHSs. In contrast, AP-1 may interact with
many more ITD-specific targets. It is known that AP-1 regulates
the inflammatory response and is involved in activating gene
expression in multiple types of cancers with an inflammatory
phenotype such as breast cancer, melanoma, and Hodgkin’s
lymphoma (Giancotti, 2006; Kappelmann et al., 2014; Kreher
et al., 2014). We previously showed that the chronic activation
of regulators of inflammatory response genes such as JUN and
IRF5 activates a Hodgkin’s lymphoma-specific gene expression
program characterized by cytokine and chemokine expression,
which during disease progression is progressively upregulated
by chronic autocrine and paracrine stimulation (Kreher et al.,
2014). It is therefore possible that STAT5 interaction with DNA
is required for the initiation of the leukemic phenotype, but during
leukemia development in patients it becomes less important due
to the progressive establishment of a FLT3-ITD-specific tran-
scriptional network that is driven by chronic inflammation and
MAPK responsive transcription factors. This feature is consistent
with our finding of the FLT3-ITD-specific upregulation of inflam-
matory response genes, such as chemokine genes, growth fac-
tor receptor genes, and genes involved in leukocyte activation
and response to bacterial stimuli.
The FLT3-ITD mutation comes with a bad prognosis, and at-
tempts to cure this type of AML using FLT3 inhibitors have met
with only limited success (Grundler et al., 2003; Levis et al.,
2011). Our system-wide studies of primary cells highlighting a
common MAPK-responsive transcriptional network are there-
fore of utmost importance for cancer therapy, which may be
applicable to ITD+ AML. Efforts to evaluate the role of different
genes within this network with respect to the maintenance of
the leukemogenic phenotype are currently underway.EXPERIMENTAL PROCEDURES
Detailed methods are in the Supplemental Information.Patient Samples
AML cells and PBSCs were purified by density gradient centrifugation. Where
the blasts were less than 92%, cells were further purified using CD34 or CD117
antibody coupled beads.DNase-Seq and ChIP-Seq
Global analyses of DHSs and RUNX1 binding, and data analyses, were per-
formed as in Ptasinska et al. (2014).ce motifs underlined, which underlay the ITD-specific DHS signature.
e and absence of stimulation for 2 hr with phorbol 12-myristate 13-acetate and
AP-1 or non-specific (NS) DNA competitors or FOS antibodies.
mismatch (MM) control siRNA, using the indicated antibodies.
V4-11 cells with either siRNA against FLT3 (left) or with the MAPK pathway
d p38, respectively (right), from three independent experiments for each gene.
G used as a control. Data are expressed relative to FOS or RUNX1 binding to a
her FLT3 or MM siRNA.
Cell Reports 12, 821–836, August 4, 2015 ª2015 The Authors 833
A B
C
D
E F
Figure 7. ITD-Specific DHS Motifs Are Occupied in ITD+ AML
(A) Model depicting the generation of DNase I footprints at DHSs.
(B) DNase I cleavage patterns within ITD1-specific footprints predicted by Wellington. Upper strand cut sites are shown in red and lower strand cut sites in green
within a 200-bp window centered on each footprint (gap), for all 5,142 ITD-specific footprints, and for those containing AP-1 sites.
(legend continued on next page)
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Mutations
Screening of DNA for mutations in the 55 AML-associated genes listed in Data
File S1 was performed by WMRGL, Birmingham Women’s Hospital.
DNA Methylation
Analyses of DNAmethylation were performed by Gen-Probe using the Illumina
450K platform.
ACCESSION NUMBERS
The DNase-seq, ChIP-seq, and mRNA array data reported in this study are
available in the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/
geo/) as a superseries under the accession number GEO:GSE64874.
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